-

Incyte to Report Second Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025.

The schedule for the press release and conference call/webcast is as follows:

  • Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET
  • Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET
  • Domestic Dial-In Number: 877-407-3042
  • International Dial-In Number: 201-389-0864
  • Conference ID Number: 13754581

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13754581.

The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

Contacts

Incyte Contacts

Media
media@incyte.com

Investors
ir@incyte.com

Incyte

NASDAQ:INCY

Release Versions

Contacts

Incyte Contacts

Media
media@incyte.com

Investors
ir@incyte.com

More News From Incyte

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

TOKYO--(BUSINESS WIRE)--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma...

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

TOKYO--(BUSINESS WIRE)--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer...

Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discover...
Back to Newsroom